by Richard Cruse | Jan 26, 2020 | News
We have been analysing the data provided by the World Federation for Hemophilia (WFH) for a number of years to develop our understanding of the market. Its Reports on the Annual Survey give details of the number of patients by country and the quantity of FVIII used....
by Richard Cruse | Nov 15, 2019 | News
Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board. Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries. He currently...
by Richard Cruse | Oct 30, 2019 | News
ProFactor Pharma Ltd (PFP) is set to transform the treatment of ‘Haemophilia A’ following the completion of its latest funding round. PFP has secured new investment of £2m in a funding round lead by the investment syndicate Kelvin Capital and supported by Ingenza Ltd...
by Richard Cruse | Dec 16, 2015 | News
Hope for Haemophiliacs Despite the controversy and disappointment emerging from the final report of the Penrose Inquiry into contaminated blood, which led to infection and death of hundreds of Scots, including haemophiliacs, new hope is emerging in a small laboratory...
by Richard Cruse | Aug 20, 2013 | News
ProFactor Pharma closed its round of financing in August 2013. The funding was provided principally by members of the Business Angel Syndicate Kelvin Capital, Glasgow, and the Scottish Investment Bank Co-investment Fund. Some of the existing shareholders, including...
